Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Hurle

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Future Oncology (London, England)|July 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapyMatteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, et al.
World Journal of Urology|January 11, 2026
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter studyPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Urologic Oncology|December 13, 2024
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapyRoberto Contieri, Francesco Claps, Rodolfo Hurle, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
Minerva Urology and Nephrology|December 3, 2024
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approachMatteo Ferro, Octavian S Tataru, Giuseppe Fallara, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
BJU International|June 25, 2025
Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancerMatteo Ferro, Michele Catellani, Roberto Bianchi, et al.
Cancers|November 13, 2021
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort AnalysisMatteo Ferro, Francesco Del Giudice, Giuseppe Carrieri, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Future Oncology (London, England)|July 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapyMatteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, et al.
World Journal of Urology|January 11, 2026
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter studyPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Urologic Oncology|December 13, 2024
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapyRoberto Contieri, Francesco Claps, Rodolfo Hurle, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
Minerva Urology and Nephrology|December 3, 2024
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approachMatteo Ferro, Octavian S Tataru, Giuseppe Fallara, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
BJU International|June 25, 2025
Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancerMatteo Ferro, Michele Catellani, Roberto Bianchi, et al.
Cancers|November 13, 2021
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort AnalysisMatteo Ferro, Francesco Del Giudice, Giuseppe Carrieri, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
Pageof 19